title: [Solutions for off-label therapy].
abstract: About 25% of administrations are for off-label indications. The treatment of many rheumatic diseases includes off-label use. Reimbursement from the health insurance is possible if no other approved therapy is available, and if scientific studies prove the effectiveness of the drug.
authors.affiliation: Rheumaklinik Berlin-Buch, Karower Strasse 11, 13125 Berlin, Germany. schmidt.wa@t-online.de
authors.forename: W A
authors.initials: WA
authors.lastname: Schmidt
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005858:Germany; D006801:Humans; D019458:Insurance Coverage / Q000331:legislation & jurisprudence; D009313:National Health Programs / Q000191:economics / Q000331:legislation & jurisprudence*; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000191:economics
chemical_list: D018501:Antirheumatic Agents